2023 Q2 Form 10-Q Financial Statement

#000149315223028954 Filed on August 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q4 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $31.65K $750.6K $170.6K
YoY Change -81.45% 152.12%
Operating Profit -$31.65K -$170.6K
YoY Change -81.45%
Interest Expense $240.0K $652.4K $157.6K
YoY Change 52.26% 48227.41%
% of Operating Profit
Other Income/Expense, Net -$90.00 $90.00
YoY Change
Pretax Income $210.0K -$98.28K -$12.99K
YoY Change -1716.63% -66.84%
Income Tax
% Of Pretax Income
Net Earnings $210.1K -$98.28K -$12.99K
YoY Change -1717.81% -66.84%
Net Earnings / Revenue
Basic Earnings Per Share $0.06 $0.00
Diluted Earnings Per Share $0.06 -$0.03 -$3.817K
COMMON SHARES
Basic Shares Outstanding 2.500M shares
Diluted Shares Outstanding 3.403M shares 3.403M shares

Balance Sheet

Concept 2023 Q2 2022 Q4 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $47.79K $117.2M
YoY Change -100.0% -99.96%
Cash & Equivalents $8.086K $47.79K $262.9K
Short-Term Investments $116.9M
Other Short-Term Assets $100.0K $143.1K $238.3K
YoY Change -58.04% 1804.93%
Inventory
Prepaid Expenses $115.6K $143.1K $238.3K
Receivables
Other Receivables
Total Short-Term Assets $123.6K $361.4K $501.2K
YoY Change -75.33% -50.02%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $20.70M $19.54M $116.9M
YoY Change -82.29% -83.26%
Other Assets
YoY Change
Total Long-Term Assets $20.67M $19.54M $116.9M
YoY Change -82.32% -83.26%
TOTAL ASSETS
Total Short-Term Assets $123.6K $361.4K $501.2K
Total Long-Term Assets $20.67M $19.54M $116.9M
Total Assets $20.79M $19.90M $117.4M
YoY Change -82.29% -83.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $607.9K $686.2K $3.535K
YoY Change 17096.21% 1464.12%
Deferred Revenue
YoY Change
Short-Term Debt $1.000M $259.1K $88.54K
YoY Change 1029.43% 192.68%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.788M $1.085M $172.1K
YoY Change 939.35% 612.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.000M $4.025M $4.025M
YoY Change -0.62% 0.0%
Total Long-Term Liabilities $4.000M $4.025M $4.025M
YoY Change -0.62% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.788M $1.085M $172.1K
Total Long-Term Liabilities $4.000M $4.025M $4.025M
Total Liabilities $5.813M $5.110M $4.197M
YoY Change 38.51% 22.33%
SHAREHOLDERS EQUITY
Retained Earnings -$5.690M -$4.920M -$3.526M
YoY Change 61.4% 42.47%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.690M -$4.919M -$3.525M
YoY Change
Total Liabilities & Shareholders Equity $20.79M $19.90M $117.4M
YoY Change -82.29% -83.06%

Cashflow Statement

Concept 2023 Q2 2022 Q4 2022 Q2
OPERATING ACTIVITIES
Net Income $210.1K -$98.28K -$12.99K
YoY Change -1717.81% -66.84%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$10.00K -$3.650K -$91.33K
YoY Change -89.05% -98.49%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$250.0K $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$250.0K $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $116.7M $116.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 250.0K 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -10.00K -3.650K -91.33K
Cash From Investing Activities -250.0K 0.000 0.000
Cash From Financing Activities 250.0K 0.000 0.000
Net Change In Cash -10.00K -3.650K -91.33K
YoY Change -89.05% -100.51%
FREE CASH FLOW
Cash From Operating Activities -$10.00K -$3.650K -$91.33K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001879373
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
ENCP Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
usd
ENCP Remeasurement For Ordinary Share To Redemption Amount
RemeasurementForOrdinaryShareToRedemptionAmount
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41070
dei Entity Registrant Name
EntityRegistrantName
ENERGEM CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Address Address Line1
EntityAddressAddressLine1
Level 3, Tower 11, Avenue 5, No. 8
dei Entity Address Address Line2
EntityAddressAddressLine2
Jalan Kerinchi, Bangsar South
dei Entity Address Address Line3
EntityAddressAddressLine3
Wilayah Persekutuan
dei Entity Address City Or Town
EntityAddressCityOrTown
Kuala Lumpur
dei Entity Address Country
EntityAddressCountry
MY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
59200
dei City Area Code
CityAreaCode
(60)
dei Local Phone Number
LocalPhoneNumber
3270 47622
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 us-gaap Cash
Cash
8086 usd
CY2022Q4 us-gaap Cash
Cash
47789 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
115556 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
143055 usd
CY2022Q4 us-gaap Other Receivables
OtherReceivables
170594 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
123642 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
361438 usd
CY2023Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
20670271 usd
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
19535946 usd
CY2023Q2 us-gaap Assets
Assets
20793913 usd
CY2022Q4 us-gaap Assets
Assets
19897384 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
607886 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
686195 usd
CY2023Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
200000 usd
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
140000 usd
CY2023Q2 ENCP Working Capital Loan
WorkingCapitalLoan
209682 usd
CY2023Q2 ENCP Extension Loan
ExtensionLoan
682373 usd
CY2022Q4 ENCP Extension Loan
ExtensionLoan
170594 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1788483 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1085331 usd
CY2023Q2 ENCP Deferred Underwriting Commission
DeferredUnderwritingCommission
4025000 usd
CY2022Q4 ENCP Deferred Underwriting Commission
DeferredUnderwritingCommission
4025000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
5813483 usd
CY2022Q4 us-gaap Liabilities
Liabilities
5110331 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
20670271 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
19706540 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5690182 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4919828 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5689841 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4919487 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20793913 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19897384 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
31653 usd
us-gaap Operating Expenses
OperatingExpenses
258576 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
170609 usd
us-gaap Operating Expenses
OperatingExpenses
241714 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-31653 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-258576 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-170609 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-241714 usd
CY2023Q2 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
241790 usd
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
451951 usd
CY2022Q2 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
157620 usd
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
169325 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
210137 usd
us-gaap Net Income Loss
NetIncomeLoss
193375 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12989 usd
us-gaap Net Income Loss
NetIncomeLoss
-72389 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3403075 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3403075 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3403075 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3403075 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3403075 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3403075 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3403075 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3403075 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3403075 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3403075 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3403075 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3403075 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4919487 usd
CY2023Q1 us-gaap Share Price
SharePrice
0.045
CY2023Q1 ENCP Stock Issued During Period Value Additional Amount Deposited Into Trust
StockIssuedDuringPeriodValueAdditionalAmountDepositedIntoTrust
-255889 usd
CY2023Q1 ENCP Remeasurement Ordinary Share To Redemption Amount
RemeasurementOrdinaryShareToRedemptionAmount
-210161 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16762 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5402299 usd
CY2023Q2 us-gaap Share Price
SharePrice
0.045
CY2023Q2 ENCP Stock Issued During Period Value Additional Amount Deposited Into Trust
StockIssuedDuringPeriodValueAdditionalAmountDepositedIntoTrust
-255889 usd
CY2023Q2 ENCP Remeasurement Ordinary Share To Redemption Amount
RemeasurementOrdinaryShareToRedemptionAmount
-241790 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
210137 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5689841 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3452832 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-59400 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3512232 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3512232 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12989 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12989 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3525221 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3525221 usd
us-gaap Net Income Loss
NetIncomeLoss
193375 usd
us-gaap Net Income Loss
NetIncomeLoss
-72389 usd
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
451951 usd
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
169325 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-27500 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
230804 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-78309 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-40336 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
60000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
60000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-249385 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-452854 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
682373 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-682373 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
682373 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
209682 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
892055 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39703 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-452854 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47789 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
715727 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8086 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
262873 usd
ENCP Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
4025000 usd
ENCP Value Of Class Ordinary Shares Subject To Redemption
ValueOfClassOrdinarySharesSubjectToRedemption
20670271 usd
ENCP Value Of Class Ordinary Shares Subject To Redemption
ValueOfClassOrdinarySharesSubjectToRedemption
116725000 usd
ENCP Remeasurement For Ordinary Share To Redemption Amount
RemeasurementForOrdinaryShareToRedemptionAmount
-451951 usd
CY2021Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
116725000 usd
CY2023Q2 us-gaap Cash
Cash
8086 usd
CY2022Q4 us-gaap Cash
Cash
47789 usd
CY2023Q2 ENCP Working Capital
WorkingCapital
1664841 usd
CY2022Q4 ENCP Working Capital
WorkingCapital
723893 usd
CY2023Q2 ENCP Percentage Of Minimum Fair Market Value Of Net Asset Held In Trust Account
PercentageOfMinimumFairMarketValueOfNetAssetHeldInTrustAccount
0.80 pure
CY2023Q2 ENCP Minimum Post Business Combination Ownership
MinimumPostBusinessCombinationOwnership
0.50 pure
CY2023Q2 ENCP Redeeming Shares More Than Aggregate Percentage
RedeemingSharesMoreThanAggregatePercentage
0.20 pure
CY2023Q2 ENCP Redemptions In Connection With Business Combination To Redeem Percentage
RedemptionsInConnectionWithBusinessCombinationToRedeemPercentage
1 pure
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9604519 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
98062139 usd
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2023Q2 us-gaap Cash
Cash
8086 usd
CY2022Q4 us-gaap Cash
Cash
47789 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000 usd
CY2023Q2 ENCP Working Capital Loan Outstanding
WorkingCapitalLoanOutstanding
209682 usd
CY2023Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zTIcTpwWVR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zs5p2EmC55h5">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Assets Held In Trust
AssetsHeldInTrust
20670271 usd
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
19706540 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
5000001 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zX4uGZK6Tp21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_869_zsyuw50dk9Th">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230630_zTXoPA7d6tMc" title="Federal depository insurance coverage amount">250,000</span>. On June 30, 2023 and December 31, 2022, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.4pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
116725000 usd
CY2023Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
111444250 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5280750 usd
CY2021Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2862500 shares
us-gaap Related Party Transaction Description Of Transaction
RelatedPartyTransactionDescriptionOfTransaction
The initial shareholders have agreed not to transfer, assign or sell any of the Class B ordinary shares (except to certain permitted transferees) until, with respect to 50% of the Class B ordinary shares, the earlier of (i) six months after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after a Business Combination, with respect to the remaining 50% of the Class B ordinary shares, upon six months after the date of the consummation of a Business Combination, or earlier, in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, share exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property.
CY2023Q2 ENCP Working Capital Loan Outstanding
WorkingCapitalLoanOutstanding
209682 usd
CY2022Q4 ENCP Working Capital Loan Outstanding
WorkingCapitalLoanOutstanding
0 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
ENCP Share Adjustment Description
ShareAdjustmentDescription
the Company issues additional shares of Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of our initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A ordinary shares (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our sponsor or its affiliates, without taking into account any founder shares held by our sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial Business Combination on the date of the consummation of our initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which we consummate our initial Business Combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price

Files In Submission

Name View Source Status
0001493152-23-028954-index-headers.html Edgar Link pending
0001493152-23-028954-index.html Edgar Link pending
0001493152-23-028954.txt Edgar Link pending
0001493152-23-028954-xbrl.zip Edgar Link pending
encp-20230630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
encp-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
encp-20230630_pre.xml Edgar Link unprocessable
encp-20230630_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending
encp-20230630_def.xml Edgar Link unprocessable